News

COVID-19 mRNA vaccines are highly effective in protecting people with immune-related inflammatory diseases against hospitalization and death, a new Canadian study suggests.

Both the National Advisory Committee on Immunization (NACI) and the Canadian Rheumatology Association (CRA) recently released their recommendation on a third dose of the COVID-19 vaccine for individuals who are immunocompromised. The Arthritis Society supports these recommendations. In order...

Treating critically ill COVID-19 patients with Roche's Actemra or Sanofi's Kevzara arthritis drugs significantly improves survival rates and reduces the amount of time patients need intensive care, study results showed on Thursday. The findings, which have not yet been peer-reviewed,...

Our Chief Science Officer, Dr. Sian Bevan, and arthritis ambassador Darlene McPherson, comment on how COVID-19 has led to a shortage of Hydroxychloroquine – a drug used to treat Rheumatoid Arthritis and Lupus – and how it's impacting patients. The Arthritis Society continues to...